IntegraGen’s Scientific Advisory Board Meets to Review latest miR-31-3p data

IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…)  » 

Interview with Bernard Courtieu appears in La Tribune

Florence Pinaud’s interview with IntegraGen CEO Bernard Courtieu as a part of her story on newer genetic sequencing technologies, potential ethical issues associated with genetic sequencing, and the need for advanced data processing in association with these technologies appears (…)  » 

EEI-Biotech Finance interviews Bernard Courtieu

Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer. 

The interview (…)  » 

miR-31-3p oncology biomarker data to be presented at ASCO 2015

Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.

The first study will report results from research conducted in cooperation (…)  » 

IntegraGen Genomics launches GeCO – an advanced genomic biostatistical consulting service

integragen-genomics-geco

IntegraGen Genomics has announced the launch of GeCo, an advanced genomic consulting service which offers statistical support to help researchers analyze and interpret complex genomic data. IntegraGen will offer researchers access to leading experts in the field of biostatistics and bioanalytics and offer support for the advanced and personalized statistical analysis of genomic (…)  »